{"filing":{"accession_number":"0001171843-26-004974","cik":"0000818686","ticker":"TEVJF","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","form":"8-K","filing_date":"2026-07-29","report_date":"2026-07-29","primary_document":"f8k_072926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/f8k_072926.htm"},"events":[{"id":21361,"run_id":19267,"accession_number":"0001171843-26-004974","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on July 29, 2026. The Item 2.02 disclosure explicitly states \"Teva Pharmaceutical Industries Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. The press release contains comprehensive quarterly financial results including revenues ($4.1 billion), net loss ($576 million), EPS ($0.49 loss), and updated 2026 guidance, making this a material earnings disclosure.","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-07-29","form":"8-K","submitted_at":null,"items":[{"id":20987,"accession_number":"0001171843-26-004974","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on July 29, 2026. The Item 2.02 disclosure explicitly states \"Teva Pharmaceutical Industries Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. The press release contains comprehensive quarterly financial results including revenues ($4.1 billion), net loss ($576 million), EPS ($0.49 loss), and updated 2026 guidance, making this a material earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:01:54.189835+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20987,"accession_number":"0001171843-26-004974","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed on July 29, 2026. The Item 2.02 disclosure explicitly states \"Teva Pharmaceutical Industries Ltd. (the 'Company') issued a press release announcing its financial results for the quarter ended June 30, 2026,\" with the full press release attached as Exhibit 99.1. The press release contains comprehensive quarterly financial results including revenues ($4.1 billion), net loss ($576 million), EPS ($0.49 loss), and updated 2026 guidance, making this a material earnings disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-29T11:01:54.189835+00:00","company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVJF","filing_date":"2026-07-29"}]}